Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network

BACKGROUND: Dose intensity and dose density of first line Platinum and Etoposide (PE) do not influence Overall Survival (OS) of Small Cell Lung Cancer (SCLC) patients. The effect of treatment length, however, remains unclear. Current guidelines recommend treating beyond 4 cycles -up to 6-, in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Sallam, Mostafa, Wong, Helen, Escriu, Carles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823940/
https://www.ncbi.nlm.nih.gov/pubmed/31675940
http://dx.doi.org/10.1186/s12890-019-0948-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823940/
https://www.ncbi.nlm.nih.gov/pubmed/31675940
http://dx.doi.org/10.1186/s12890-019-0948-x

Ejemplares similares